Pharma market Access Risk Assessment
Market access creates one of the largest sources of unpriced value risk in pharma.
Long before launch or negotiation, payer behavior, evidence expectations, and reimbursement dynamics actively shape commercial exposure—yet teams rarely assess that exposure with discipline.
MARA provides market access pharma risk assessment as a standalone strategic service that supports pricing, reimbursement, and HTA decisions.
As a result, organizations often lose value silently. Delays emerge, pricing erodes, HTA outcomes disappoint, and negotiating leverage weakens—not because teams fail to execute, but because they never made risk visible early enough.
MARA’s market access pharma risk assessment addresses that gap. It makes access risk explicit and provides a structured, independent view before critical commercial and development commitments lock in.
Market Access Risks in Pharma
Market access risk in pharma is systemic rather than incidental. It arises from predictable patterns across pricing, evidence, and payer response. Nevertheless, many organizations still treat it reactively.
Consequently, teams face outcomes such as:
Delayed or restricted reimbursement despite regulatory success
Price erosion driven by payer challenge or precedent effects
Negative or conditional HTA outcomes that limit commercial upside
Loss of leverage once negotiation positions harden
Strategic inflexibility late in development or at launch
Importantly, these risks rarely appear as single failures. Instead, they accumulate over time and erode asset value before corrective action remains possible.
Our Market Access Pharma Risk Assessment
MARA’s market access pharma risk assessment is a standalone strategic service that identifies, quantifies, and prioritizes pricing, reimbursement, and HTA risk at the asset level.
The assessment focuses on the factors that most reliably shape payer and HTA outcomes. As a result, it highlights where value remains most vulnerable and explains why that exposure exists.
Rather than documenting process, the assessment isolates risk signals, including:
Where access assumptions weaken under scrutiny
Where payer resistance is most likely to emerge
Where evidence, pricing, or sequencing decisions amplify downside
Ultimately, the assessment delivers a clear, decision-ready view of market access risk—independent, comparable, and grounded in observed access outcomes.
Decisions Informed by the Risk Assessment
Organizations use this assessment before commitments become difficult or irreversible. Therefore, it directly informs decisions such as:
Pricing corridor definition and downside exposure
Evidence generation and prioritization trade-offs
Launch sequencing and geographic strategy
Portfolio prioritization and capital allocation
Go / no-go decisions ahead of late-stage investment
Leadership alignment on acceptable access risk prior to commitment
For this reason, the assessment supports executive judgment precisely where uncertainty carries material financial consequence.
What You Receive
The market access pharma risk assessment produces decision assets, not generic outputs.
Specifically, you receive:
A clear view of where market access risk concentrates
Prioritized exposure across key access drivers
A concise articulation of downside scenarios
A structured risk profile consolidating exposure across key access dimensions
A basis for comparing assets or strategies on access risk
In short, the emphasis remains clarity: what matters, where risk sits, and what it means for value.
Who Uses Market Access Risk Assessment
Senior decision-makers within pharmaceutical sector use this service to protect value and set strategic direction, including:
Global and regional Heads of Market Access
Pricing and Market Access leadership teams
Commercial and portfolio strategy leaders
Executive committees evaluating late-stage assets
Investors assessing access risk pre-commitment
Accordingly, the service does not target training, operational execution, or early-career audiences.
Why a Risk-Based Market Access Model
Traditional market access approaches often prioritize optimization after teams establish positions. By then, however, options narrow and risk has already materialized.
A risk-based model shifts the focus upstream:
From explanation to exposure
From reaction to prevention
From process to decision relevance
Because organizations identify access risk earlier, they retain strategic flexibility and protect value before erosion occurs.
How the Assessment Is Deployed
MARA deploys the market access pharma risk assessment as a core, standalone engagement.
Teams typically use it:
Ahead of launch planning
During late-stage development
Before geographic expansion
When reassessing access assumptions after feedback
Engagements are typically structured as a time-bounded assessment with decision-ready outputs. Importantly, the assessment functions as a discrete decision input—not as a diagnostic prelude to consulting.
Assess Your Market Access Risk
If market access risk materially affects asset value, organizations should assess it explicitly.
MARA provides an independent, structured view of market access risk to support informed, high-stakes decisions.
For organizations where market access pharma risk materially affects asset value, explicit assessment is critical.
To discuss a market access risk assessment for an asset or portfolio, contact MARA.
Explore related insights and services in our Services section.